Company Of The Day: Merck

+3.10%
Upside
131
Market
135
Trefis
MRK: Merck logo
MRK
Merck

What?

Merck (NYSE:MRK) is preparing a new formulation for its blockbuster cancer immunotherapy Keytruda, which could be injected under the skin.

Why?

Relevant Articles
  1. Is Johnson & Johnson Stock A Better Pick Over Merck?
  2. Is Merck Stock Fully Valued At $130?
  3. Will Higher Keytruda Sales Drive Merck’s Q1
  4. After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
  5. At $100 Does Merck Stock Have Room For Growth?
  6. Should You Pick Merck Stock Over Coca-Cola?

Keytruda will see patents start to expire in 2028. Merck believes that the new formulation has the potential to be novel, non-obvious, and useful, implying that it could receive a new patent.

So What?

Keytruda is Merck’s most important drug, generating over $17 billion in sales in 2021. These developments could potentially help the company hold off on a sales decline.

See Our Complete Analysis For Merck

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns Dec 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 MRK Return 0% 44% 87%
 S&P 500 Return 0% -15% 82%
 Trefis Multi-Strategy Portfolio 1% -17% 230%

[1] Month-to-date and year-to-date as of 12/5/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market-Beating Portfolios

See all Trefis Price Estimates